Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1991-9-19
|
| pubmed:abstractText |
As of July 1, 1991, HCFA will reimburse for Epoetin alfa self-administered by home-based dialysis patients. Implications of this change, including the impact on patients and the changes that will be required to assure effective nursing assessment and optimal patient management, are reviewed.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
N
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
8750-0779
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
408-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading | |
| pubmed:year |
1991
|
| pubmed:articleTitle |
Case management of the anemic patient. Epoetin alfa: focus on self-administration.
|
| pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|